Self-management interventions for men with lower urinary tract symptoms: A systematic review and meta-analysis of randomized controlled trials
Abstract
INTRODUCTION
Lower urinary tract symptoms (LUTS) significantly impact men's quality of life and can cause bothersome symptoms, which often interfere with daily functioning and contribute to psychological distress. While pharmacological and surgical treatments are effective, they can have side effects, and not all men require or desire these interventions. The aim of this study is to assess the impact of self-management interventions on symptom severity.
METHODS
We conducted a systematic search across multiple databases, including PubMed, Embase, and Cochrane Library, from inception to August 2024. We identified randomized controlled trials (RCTs) assessing self-management interventions for LUTS in men. Studies were evaluated for quality and analyzed for outcomes on BPH Impact Index, International Prostate Symptom Score (IPSS), and QoL. Publication bias and heterogeneity were examined through LFK indices, sensitivity analyses, and Doi plots.
RESULTS
Self-management significantly reduced the BPH Impact Index at 3 months (SMD: -0.73; p = 0.0003) and 6 months (SMD: -0.95; p = 0.05), though publication bias was indicated. The IPSS decreased significantly at 3 months (MD: -5.52; p < 0.01), 6 months (MD: -5.50; p = 0.002), and 12 months (MD: -3.51; p = 0.01). Quality of life also improved at 6 and 12 months (SMD: -0.34, p = 0.002, and SMD: -0.30, p < 0.01, respectively). Sensitivity analysis confirmed the consistency of these findings after adjusting for study heterogeneity.…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.